Cardurion registers Phase 2 CALIBRATE-HF trial of CaMKII inhibitor CRD-4730 in HFrEF

Cardurion Pharmaceuticals had one registry update posted this week.

• Cardurion is recruiting for "CALIBRATE-HF" (NCT07750873), a Phase 2 trial of CRD-4730, described as a calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor¹, in patients with heart failure with reduced ejection fraction. The study is a global, multi-center, randomized, double-blind, parallel-group, placebo-controlled trial evaluating CRD-4730 added to guideline directed medical therapy in HFrEF participants¹, with an estimated enrollment of 525 participants¹ and a primary outcome of change from baseline in a composite z-score at 24 weeks, combining six endpoints including NT-proBNP, left ventricular volume indices, E/e' ratio, global longitudinal strain, and left atrial volume index¹. The trial's actual start date is listed as 2026-07-15¹, with estimated primary completion in 2028-09¹.